The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. (original) (raw)

Research Article Free access | 10.1172/JCI1269

M F Fromm, C Wandel, B Leake, A J Wood, D M Roden, and G R Wilkinson

Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6602, USA.

Find articles by Kim, R. in:[JCI](/search/results?q=author.first%5Fname%3A%22R B%22+author.last%5Fname%3A%22Kim%22&search%5Ftype=advanced) |PubMed |Google Scholar

Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6602, USA.

Find articles by Fromm, M. in:[JCI](/search/results?q=author.first%5Fname%3A%22M F%22+author.last%5Fname%3A%22Fromm%22&search%5Ftype=advanced) |PubMed |Google Scholar

Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6602, USA.

Find articles by Wandel, C. in:JCI |PubMed |Google Scholar

Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6602, USA.

Find articles by Leake, B. in:JCI |PubMed |Google Scholar

Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6602, USA.

Find articles by Wood, A. in:[JCI](/search/results?q=author.first%5Fname%3A%22A J%22+author.last%5Fname%3A%22Wood%22&search%5Ftype=advanced) |PubMed |Google Scholar

Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6602, USA.

Find articles by Roden, D. in:[JCI](/search/results?q=author.first%5Fname%3A%22D M%22+author.last%5Fname%3A%22Roden%22&search%5Ftype=advanced) |PubMed |Google Scholar

Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6602, USA.

Find articles by Wilkinson, G. in:[JCI](/search/results?q=author.first%5Fname%3A%22G R%22+author.last%5Fname%3A%22Wilkinson%22&search%5Ftype=advanced) |PubMed |Google Scholar

Published January 15, 1998 -More info

Published January 15, 1998 -Version history

View PDF

Abstract

Currently available HIV-1 protease inhibitors are potent agents in the therapy of HIV-1 infection. However, limited oral absorption and variable tissue distribution, both of which are largely unexplained, complicate their use. We tested the hypothesis that P-glycoprotein is an important transporter for these agents. We studied the vectorial transport characteristics of indinavir, nelfinavir, and saquinavir in vitro using the model P-glycoprotein expressing cell lines L-MDR1 and Caco-2 cells, and in vivo after intravenous and oral administration of these agents to mice with a disrupted mdr1a gene. All three compounds were found to be transported by P-glycoprotein in vitro. After oral administration, plasma concentrations were elevated 2-5-fold in mdr1a (-/-) mice and with intravenous administration, brain concentrations were elevated 7-36-fold. These data demonstrate that P-glycoprotein limits the oral bioavailability and penetration of these agents into the brain. This raises the possibility that higher HIV-1 protease inhibitor concentrations may be obtained by targeted pharmacologic inhibition of P-glycoprotein transport activity.

Version history